Caris Life Sciences (NASDAQ:CAI) Stock Keeps “Buy” Rating at BTIG Research

Caris Life Sciences (NASDAQ:CAI)‘s stock had its “buy” rating reiterated by BTIG Research in a research note issued on Thursday, Benzinga reports. They presently have a $38.00 target price on the stock. BTIG Research‘s price objective would suggest a potential upside of 14.39% from the stock’s previous close.

Several other equities analysts have also commented on CAI. Canaccord Genuity Group upped their price target on shares of Caris Life Sciences from $22.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. UBS Group set a $38.00 price objective on shares of Caris Life Sciences in a research note on Thursday. Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. TD Cowen reissued a “buy” rating on shares of Caris Life Sciences in a research report on Thursday. Finally, Evercore reaffirmed an “outperform” rating and set a $26.00 price target on shares of Caris Life Sciences in a research report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.91.

Caris Life Sciences Stock Up 1.1%

Shares of NASDAQ:CAI opened at $33.22 on Thursday. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. The firm has a market cap of $9.39 billion, a price-to-earnings ratio of 91.25 and a beta of 0.71. The stock’s 50-day moving average price is $29.52 and its two-hundred day moving average price is $21.74. Caris Life Sciences has a 12-month low of $14.19 and a 12-month high of $36.50.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a net margin of 10.62% and a return on equity of 18.77%. The business had revenue of $275.36 million for the quarter. During the same quarter in the previous year, the company earned $0.08 earnings per share. The company’s revenue was up 27.0% on a year-over-year basis. On average, research analysts forecast that Caris Life Sciences will post 0.13 EPS for the current year.

Insider Buying and Selling at Caris Life Sciences

In other news, insider Brian Brille sold 400,000 shares of Caris Life Sciences stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the sale, the insider owned 230,303 shares in the company, valued at $6,985,089.99. This trade represents a 63.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Russel Denton sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total transaction of $238,650.00. Following the transaction, the insider directly owned 174,855 shares in the company, valued at approximately $5,563,886.10. The trade was a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,004,712 shares of company stock valued at $27,205,419 over the last 90 days. 50.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Caris Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PointState Capital LP purchased a new position in Caris Life Sciences in the 2nd quarter valued at about $121,690,000. BlackRock Inc. acquired a new position in shares of Caris Life Sciences in the second quarter worth about $98,666,000. Canada Pension Plan Investment Board acquired a new position in shares of Caris Life Sciences in the second quarter worth about $24,502,000. Bank of America Corp DE purchased a new position in Caris Life Sciences in the second quarter valued at about $21,395,000. Finally, Amundi boosted its holdings in Caris Life Sciences by 5,709.5% in the second quarter. Amundi now owns 1,218,364 shares of the company’s stock valued at $21,711,000 after purchasing an additional 1,197,392 shares during the last quarter.

Caris Life Sciences News Roundup

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Caris raised its 2026 revenue guidance to $1.04 billion–$1.05 billion, implying 28%–29% annual growth. The company attributed its results to demand for molecular profiling services, including about 61,500 clinical cases and more than 358,000 oncology tests. Caris Q3 results and increased guidance
• Positive Sentiment: Third-quarter revenue rose 27% year over year to $275.4 million, while earnings of $0.05 per share beat analysts’ $0.03 estimate. The revenue growth and earnings beat are supportive signals for investors. Caris Q3 earnings and revenue beat estimates
• Neutral Sentiment: A valuation analysis framed CAI as potentially 14% below fair value following the raised outlook. That estimate is model-dependent and does not guarantee further share gains. Caris valuation analysis
• Negative Sentiment: Profitability was weaker year over year: net income fell 37% amid higher expenses, and EPS declined from $0.08 in the year-ago quarter to $0.05. This tempers the positive revenue and guidance news. Caris Q3 net income and outlook

Caris Life Sciences Company Profile

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.